Novo Nordisk A/S specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- products for treating diabetes and obesity (86.4%);
- hemophilia treatment products (7.3%): mainly injections of protein;
- growth hormones (5.1%): used for treatment of growth deficiencies in children;
- hormone replacement products (1.2%): used for treatment of the menopause and prevention of osteoporosis.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (26.8%), the United States (44.8%), North America (3%), China (11.4%) and other (14%).
Number of employees : 47 792 people.
2020 2021 Delta Diabetes and Obesity Care 108 020.00 85.1% 121 597.00 86.4% +12.57% Biopharm 18 926.00 14.9% 19 203.00 13.6% +1.46%
DKK in Million
2020 2021 Delta United States 57 824.00 45.6% 63 009.00 44.8% +8.97% EMEA 34 297.00 27% 37 706.00 26.8% +9.94% Rest of the World 17 448.00 13.7% 19 812.00 14.1% +13.55% China 14 084.00 11.1% 16 019.00 11.4% +13.74% Canada 3 293.00 2.6% 4 254.00 3% +29.18%
DKK in Million
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
10
537,000,000
0
0.0% 0
0.0% 69.6%
Stock B
1
1,742,564,000
1,586,735,093
91.1% 33,526,721
1.9%
Shareholders Novo Nordisk A/S (DK0060534915) Novo Nordisk A/S (US)
Name Equities % Novo Holdings A/S (Investment Company) 110,519,000
6.34% The Vanguard Group, Inc. 43,126,750
2.47% Norges Bank Investment Management 39,877,804
2.29% BlackRock Fund Advisors 28,057,815
1.61% Capital Research & Management Co. (World Investors) 24,928,970
1.43% BlackRock Investment Management (UK) Ltd. 21,613,860
1.24% Fundsmith LLP 21,489,877
1.23% Novo Nordisk A/S 14,281,381
0.82% BlackRock Advisors (UK) Ltd. 12,827,671
0.74% Handelsbanken Fonder AB 12,289,868
0.71%
Name Equities % Renaissance Technologies LLC 18,383,971
1.06% Fisher Asset Management LLC 15,911,102
0.91% United States Trust Co., NA 13,127,240
0.75% Jackson Square Partners LLC 6,639,477
0.38% Loomis, Sayles & Co. LP 5,903,149
0.34% Jennison Associates LLC 5,527,477
0.32% Capital Research & Management Co. (International Investors) 5,325,550
0.31% Fayez Sarofim & Co. 4,767,163
0.27% Cambiar Investors LLC 4,608,255
0.26% Managed Account Advisors LLC 4,478,426
0.26%
Name Equities % Valuation
NOVO NORDISK A/S (NOVO B) 14,281,381
0.82%
1,578,674,567 USD
NNIT A/S (NNIT) 4,375,000
17.5%
40,569,069 USD
INNATE PHARMA (IPH) 9,817,546
12.3%
29,658,119 USD
- Main Market Large
- OMX Copenhagen 25 / Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, PEA, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
- Bloomberg Code :
NOVOB:DC
- Reuters Code :
NOVOb.CO
- Datastream Code :
Company contact information
Novo Nordisk lifts 2022 outlook after strong quarter, shares jump
NOVO NORDISK AS
Sector Other Pharmaceuticals
Connections : Novo Nordisk A/S
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
